While noting improvements, two Duke studies find doctors still not using drugs shown to be beneficial in clinical trials

March 19, 2001

Orlando, FL - Two different analyses by Duke University Medical Center cardiologists have shown that while multi-center clinical trials involving thousands of patients have clearly demonstrated that certain drugs can improve the outcomes for heart patients and save lives, the message is not being uniformly heard by physicians.

During the past decade, large-scale randomized clinical trials have shown the effectiveness of such agents as beta blockers, ACE inhibitors and aspirin in reducing the number of deaths due to heart disease. While one might assume that the results of these trials would change the way physicians practice, that is not always the case, the researchers say.

The Duke studies show, for example, that the acceptance rates by doctors of different classes of new drugs varies widely, and can vary from region to region across North America. A preliminary analysis by the Duke researchers determined that if every patient who was an appropriate candidate for one of the proven therapies actually received the therapy, more than 80,000 lives a year could be saved.
-end-
The results of the two Duke analyses were prepared for presentation during the 50th annual scientific sessions of the American College of Cardiology.

Note to editors: Dr. Christopher Granger can be reached at 919-668-8900, grang001@mc.duke.edu, and Dr. M. Cecilia Bahit can be reached at 919-668-8700, Bahit001@mc.duke.edu

Duke University Medical Center

Related Drugs Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

Read More: Drugs News and Drugs Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.